Alpha emitter radium-223 and survival in metastatic prostate cancer

Autoria(s): Parker, C; Nilsson, S; Heinrich, D; Helle, S I; O'Sullivan, J M; Fosså, S D; Chodacki, A; Wiechno, P; Logue, J; Seke, M; Widmark, A; Johannessen, D C; Hoskin, P; Bottomley, D; James, N D; Solberg, A; Syndikus, I; Kliment, J; Wedel, S; Boehmer, S; Dall'Oglio, M; Franzén, L; Coleman, R; Vogelzang, N J; O'Bryan-Tear, C G; Staudacher, K; Garcia-Vargas, J; Shan, M; Bruland, Ø S; Sartor, O; ALSYMPCA Investigators
Data(s)

18/07/2013
Resumo

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.
Identificador

http://pure.qub.ac.uk/portal/en/publications/alpha-emitter-radium223-and-survival-in-metastatic-prostate-cancer(6de340c0-8883-44e1-ab6b-6ee6b57165b7).html

http://dx.doi.org/10.1056/NEJMoa1213755
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Parker , C , Nilsson , S , Heinrich , D , Helle , S I , O'Sullivan , J M , Fosså , S D , Chodacki , A , Wiechno , P , Logue , J , Seke , M , Widmark , A , Johannessen , D C , Hoskin , P , Bottomley , D , James , N D , Solberg , A , Syndikus , I , Kliment , J , Wedel , S , Boehmer , S , Dall'Oglio , M , Franzén , L , Coleman , R , Vogelzang , N J , O'Bryan-Tear , C G , Staudacher , K , Garcia-Vargas , J , Shan , M , Bruland , Ø S , Sartor , O & ALSYMPCA Investigators 2013 , ' Alpha emitter radium-223 and survival in metastatic prostate cancer ' New England Journal of Medicine , vol 369 , no. 3 , pp. 213-23 . DOI: 10.1056/NEJMoa1213755
Palavras-Chave #Aged #Aged, 80 and over #Bone Neoplasms #Double-Blind Method #Humans #Isotopes #Kaplan-Meier Estimate #Male #Middle Aged #Prostatic Neoplasms #Radium #/dk/atira/pure/subjectarea/asjc/2700 #Medicine(all)
Tipo

article
Acesso ao item digital